Comparative metabolism and tolerability of racemic primaquine and its enantiomers in human volunteers during 7-day administration.

Primaquine (PQ) is an 8-aminoquinoline antimalarial, active against dormant hypnozoites and mature gametocytes. PQ is currently used for radical cure and prevention of malaria transmission. PQ is a racemic drug and since the metabolism and pharmacology of PQ's enantiomers have been shown to be divergent, the objectives of this study were to evaluate the comparative tolerability and metabolism of PQ with respect to its two enantiomers in human volunteers in a 7 days' treatment schedule.

Comparative single dose pharmacokinetics and metabolism of racemic primaquine and its enantiomers in human volunteers.

Primaquine (PQ) is a racemic drug used in treatment of malaria for six decades. Recent studies suggest that the two enantiomers of PQ are differentially metabolized in animals, and this results in different pharmacological and toxicological profiles. The current study characterizes the pharmacokinetic (PK) properties, metabolism and tolerability of the individual enantiomers of PQ in healthy human volunteers with normal glucose-6-phosphate dehydrogenase (G6PD) activity.

A mathematical model to assess the influence of hematocrit on point of care glucose meter performance.

Objectives: To develop and apply a mathematical model of the relationship between hematocrit, meter glucose and reference glucose concentrations as a tool for evaluation of whole blood glucose meters.

Design And Methods: Patient blood gas specimens were used to compare the LifeScan SureStep Flexx and the Nova StatStrip glucose meters with reference results obtained from a Radiometer 725 blood gas analyzer. Linear regression analysis was conducted to determine the extent that patient hematocrit and reference glucose concentrations predicted the performance of the glucose meters.